PMID- 28787954
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1996-1944 (Print)
IS  - 1996-1944 (Electronic)
IS  - 1996-1944 (Linking)
VI  - 8
IP  - 2
DP  - 2015 Feb 5
TI  - Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures 
      Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery 
      System.
PG  - 519-534
LID - 10.3390/ma8020519 [doi]
AB  - An oral medication of a molecular targeted drug, lapatinib, is taken regularly to 
      maintain the drug concentration within the desired therapeutic levels. To 
      alleviate the need for such cumbersome administration schedules in several drugs, 
      advanced drug delivery systems (DDSs), which can provide time-controlled and 
      sustained drug release, have recently received significant attention. A 
      biodegradable synthetic polymer, such as polycaprolactone (PCL), is usually used 
      as a carrier material for DDSs. In this paper, lapatinib powder-entrapped, PCL 
      microstructures were fabricated with a precise X-ray lithography-based method. In 
      vitro experiments on HER2 positive-human gastric cancer derived NCI-N87 cells 
      were performed to appraise the drug release characteristics of the fabricated 
      DDSs. The in vitro results indicate that after the X-ray lithography process, the 
      lapatinib powder is still working well and show time- and dose- dependent drug 
      release efficiencies. The cell growth inhibition characteristics of one hundred 
      40-mum sized microstructures were similar to those of a 1 muM lapatinib solution 
      for over 144 h. In conclusion, the developed lapatinib-entrapped PCL 
      microstructures can be used in molecular targeted delivery and sustained release 
      as effective cancer-targeted DDSs.
FAU - Jeong, Eun-Goo
AU  - Jeong EG
AD  - Cancer Research Institute, Seoul National University College of Medicine, Seoul 
      110-799, Korea. megablast@snu.ac.kr.
FAU - Yoo, Hyung Jung
AU  - Yoo HJ
AD  - Inter-university Semiconductor Research Center, Automation System Research 
      Institute, School of Electrical Engineering and Computer Science, Seoul National 
      University, Seoul 151-744, Korea. yhj@snu.ac.kr.
FAU - Song, Byeonghwa
AU  - Song B
AD  - Inter-university Semiconductor Research Center, Automation System Research 
      Institute, School of Electrical Engineering and Computer Science, Seoul National 
      University, Seoul 151-744, Korea. bhsong@snu.ac.kr.
FAU - Kim, Hwang-Phill
AU  - Kim HP
AD  - Cancer Research Institute, Seoul National University College of Medicine, Seoul 
      110-799, Korea. phill1@snu.ac.kr.
FAU - Han, Sae-Won
AU  - Han SW
AD  - Cancer Research Institute, Seoul National University College of Medicine, Seoul 
      110-799, Korea. saewon1@snu.ac.kr.
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul 
      110-744, Korea. saewon1@snu.ac.kr.
FAU - Kim, Tae-You
AU  - Kim TY
AD  - Cancer Research Institute, Seoul National University College of Medicine, Seoul 
      110-799, Korea. kimty@snu.ac.kr.
AD  - Department of Internal Medicine, Seoul National University Hospital, Seoul 
      110-744, Korea. kimty@snu.ac.kr.
AD  - Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School 
      of Convergence Science and Technology, Seoul National University College of 
      Medicine, Seoul 110-799, Korea. kimty@snu.ac.kr.
FAU - Cho, Dong-Il Dan
AU  - Cho DD
AD  - Inter-university Semiconductor Research Center, Automation System Research 
      Institute, School of Electrical Engineering and Computer Science, Seoul National 
      University, Seoul 151-744, Korea. dicho@snu.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20150205
PL  - Switzerland
TA  - Materials (Basel)
JT  - Materials (Basel, Switzerland)
JID - 101555929
PMC - PMC5455267
OTO - NOTNLM
OT  - biodegradable polymer
OT  - drug delivery system (DDS)
OT  - gastric cancer
OT  - lapatinib
OT  - molecular targeted therapy
OT  - polycaprolactone (PCL)
OT  - sustained drug release
COIS- The authors declare no conflict of interest.
EDAT- 2015/02/05 00:00
MHDA- 2015/02/05 00:01
PMCR- 2015/02/05
CRDT- 2017/08/10 06:00
PHST- 2014/12/01 00:00 [received]
PHST- 2015/01/16 00:00 [revised]
PHST- 2015/01/30 00:00 [accepted]
PHST- 2017/08/10 06:00 [entrez]
PHST- 2015/02/05 00:00 [pubmed]
PHST- 2015/02/05 00:01 [medline]
PHST- 2015/02/05 00:00 [pmc-release]
AID - ma8020519 [pii]
AID - materials-08-00519 [pii]
AID - 10.3390/ma8020519 [doi]
PST - epublish
SO  - Materials (Basel). 2015 Feb 5;8(2):519-534. doi: 10.3390/ma8020519.